• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The emergence of Ephexin5 as a therapeutic target in Alzheimer's disease.

作者信息

Cook Emily K, Sell Gabrielle L, Schaffer Thomas B, Margolis Seth S

机构信息

a Department of Biological Chemistry , The Johns Hopkins University School of Medicine , Baltimore , MD , USA.

b Center for Neuroscience , University of California , Davis , CA , USA.

出版信息

Expert Opin Ther Targets. 2019 Apr;23(4):263-265. doi: 10.1080/14728222.2019.1586884. Epub 2019 Mar 5.

DOI:10.1080/14728222.2019.1586884
PMID:30810053
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6715421/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6233/6715421/642ab488b5b1/nihms-1536633-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6233/6715421/642ab488b5b1/nihms-1536633-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6233/6715421/642ab488b5b1/nihms-1536633-f0001.jpg

相似文献

1
The emergence of Ephexin5 as a therapeutic target in Alzheimer's disease.埃菲辛5（Ephexin5）作为阿尔茨海默病治疗靶点的出现。
Expert Opin Ther Targets. 2019 Apr;23(4):263-265. doi: 10.1080/14728222.2019.1586884. Epub 2019 Mar 5.
2
Reducing expression of synapse-restricting protein Ephexin5 ameliorates Alzheimer's-like impairment in mice.降低突触限制蛋白Ephexin5的表达可改善小鼠的阿尔茨海默氏症样损伤。
J Clin Invest. 2017 May 1;127(5):1646-1650. doi: 10.1172/JCI85504. Epub 2017 Mar 27.
3
Inhibition of MK2 kinase as a potential therapeutic target to control neuroinflammation in Alzheimer's disease.
Expert Opin Ther Targets. 2021 Apr;25(4):243-247. doi: 10.1080/14728222.2021.1924151. Epub 2021 May 10.
4
How to address the complexity of multi-targeted drug discovery for Alzheimer's disease?如何应对针对阿尔茨海默病的多靶点药物研发的复杂性？
Expert Opin Drug Discov. 2024 Oct;19(10):1149-1152. doi: 10.1080/17460441.2024.2385576. Epub 2024 Jul 29.
5
Alzheimer's disease: new perspectives on therapeutic targets and pathways. Foreword.阿尔茨海默病：治疗靶点与途径的新视角。前言。
Mol Neurobiol. 2012 Aug;46(1):1-2. doi: 10.1007/s12035-012-8306-5.
6
Alzheimer's disease market: hope deferred.阿尔茨海默病市场：希望落空。
Nat Rev Drug Discov. 2013 Jan;12(1):19-20. doi: 10.1038/nrd3922.
7
A map of Alzheimer's disease-signaling pathways: a hope for drug target discovery.阿尔茨海默病信号通路图谱：药物靶点发现的希望。
Clin Pharmacol Ther. 2013 May;93(5):399-401. doi: 10.1038/clpt.2013.37. Epub 2013 Feb 20.
8
Triple GLP-1/GIP/glucagon receptor agonists, a potential novel treatment strategy in Alzheimer's disease.三重GLP-1/GIP/胰高血糖素受体激动剂，一种治疗阿尔茨海默病的潜在新策略。
Expert Opin Investig Drugs. 2019 Jan;28(1):93-97. doi: 10.1080/13543784.2019.1552677. Epub 2018 Dec 1.
9
Dysregulation of Rab5-mediated endocytic pathways in Alzheimer's disease.阿尔茨海默病中 Rab5 介导的内吞途径失调。
Traffic. 2018 Apr;19(4):253-262. doi: 10.1111/tra.12547. Epub 2018 Feb 5.
10
Abnormal kalirin signaling in neuropsychiatric disorders.神经精神疾病中异常的卡里林信号传导。
Brain Res Bull. 2014 Apr;103:29-38. doi: 10.1016/j.brainresbull.2013.12.006. Epub 2013 Dec 12.

引用本文的文献

1
Activity-dependent regulation of Cdc42 by Ephexin5 drives synapse growth and stabilization.Ephexin5对Cdc42的活性依赖性调节驱动突触生长和稳定。
Sci Adv. 2025 Mar 28;11(13):eadp5782. doi: 10.1126/sciadv.adp5782. Epub 2025 Mar 26.
2
Deleting a UBE3A substrate rescues impaired hippocampal physiology and learning in Angelman syndrome mice.删除UBE3A 底物可挽救 Angelman 综合征小鼠受损的海马生理学和学习能力。
Sci Rep. 2021 Sep 30;11(1):19414. doi: 10.1038/s41598-021-97898-w.

本文引用的文献

1
PKCε Inhibits Neuronal Dendritic Spine Development through Dual Phosphorylation of Ephexin5.蛋白激酶 Cε 通过双重磷酸化 Ephexin5 抑制神经元树突棘发育。
Cell Rep. 2018 Nov 27;25(9):2470-2483.e8. doi: 10.1016/j.celrep.2018.11.005.
2
Alzheimer's disease (AD) therapeutics - 1: Repeated clinical failures continue to question the amyloid hypothesis of AD and the current understanding of AD causality.阿尔茨海默病（AD）治疗药物 - 1：反复的临床失败继续质疑 AD 的淀粉样蛋白假说和对 AD 因果关系的现有理解。
Biochem Pharmacol. 2018 Dec;158:359-375. doi: 10.1016/j.bcp.2018.09.026. Epub 2018 Sep 29.
3
Reducing expression of synapse-restricting protein Ephexin5 ameliorates Alzheimer's-like impairment in mice.降低突触限制蛋白Ephexin5的表达可改善小鼠的阿尔茨海默氏症样损伤。
J Clin Invest. 2017 May 1;127(5):1646-1650. doi: 10.1172/JCI85504. Epub 2017 Mar 27.
4
Discontinuation, Efficacy, and Safety of Cholinesterase Inhibitors for Alzheimer's Disease: a Meta-Analysis and Meta-Regression of 43 Randomized Clinical Trials Enrolling 16 106 Patients.胆碱酯酶抑制剂治疗阿尔茨海默病的停药、疗效和安全性：43 项纳入 16106 例患者的随机临床试验的荟萃分析和荟萃回归。
Int J Neuropsychopharmacol. 2017 Jul 1;20(7):519-528. doi: 10.1093/ijnp/pyx012.
5
Memantine monotherapy for Alzheimer's disease: a systematic review and meta-analysis.美金刚单药治疗阿尔茨海默病：一项系统评价与荟萃分析。
PLoS One. 2015 Apr 10;10(4):e0123289. doi: 10.1371/journal.pone.0123289. eCollection 2015.
6
Reversing synapse loss in Alzheimer's disease: Rho-guanosine triphosphatases and insights from other brain disorders.逆转阿尔茨海默病中的突触丧失：Rho鸟苷三磷酸酶及其他脑部疾病的启示
Neurotherapeutics. 2015 Jan;12(1):19-28. doi: 10.1007/s13311-014-0328-4.
7
Caspase-2 is required for dendritic spine and behavioural alterations in J20 APP transgenic mice.Caspase-2 对于 J20 APP 转基因小鼠的树突棘和行为改变是必需的。
Nat Commun. 2013;4:1939. doi: 10.1038/ncomms2927.
8
2011 Alzheimer's disease facts and figures.2011 年阿尔茨海默病事实和数据。
Alzheimers Dement. 2011 Mar;7(2):208-44. doi: 10.1016/j.jalz.2011.02.004.
9
Reversing EphB2 depletion rescues cognitive functions in Alzheimer model.逆转 EphB2 耗竭可挽救阿尔茨海默病模型中的认知功能。
Nature. 2011 Jan 6;469(7328):47-52. doi: 10.1038/nature09635. Epub 2010 Nov 28.
10
EphB-mediated degradation of the RhoA GEF Ephexin5 relieves a developmental brake on excitatory synapse formation.EphB 介导的 RhoA GEF Ephexin5 的降解解除了兴奋性突触形成的发育性阻滞。
Cell. 2010 Oct 29;143(3):442-55. doi: 10.1016/j.cell.2010.09.038.